Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Collier

Showing results (361-370 of 508) with videos related to

Pageof 51
Sort By:
AIDS Research and Therapy|January 5, 2023
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistanceRobert A Salata, Beatriz Grinsztejn, Justin Ritz, et al.
The Journal of Infectious Diseases|April 25, 2001
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDSM M Berrey, T Schacker, A C Collier, et al.
Annals of Internal Medicine|July 4, 2001
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV diseaseE L Murphy, A C Collier, L A Kalish, et al.
Optics Express|October 6, 2012
High-energy, ceramic-disk Yb:LuAG laser amplifierM Siebold, M Loeser, F Roeser, et al.
The Lancet. HIV|June 1, 2016
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyAlberto M La Rosa, Linda J Harrison, Babafemi Taiwo, et al.
The New England Journal of Medicine|August 17, 1995
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 20, 2011
Clinical variables identify seronegative HCV co-infection in HIV-infected individualsAjay R Bharti, Scott L Letendre, Tanya Wolfson, et al.
The Journal of Infectious Diseases|July 28, 2011
Identifying the early post-HIV antibody seroconversion periodFrederick M Hecht, Robert Wellman, Michael P Busch, et al.
The Journal of Infectious Diseases|April 5, 2022
Reply to Bottanelli et alJoshua C Cyktor, Ronald J Bosch, Hanna Mar, et al.
Pageof 51

Showing results (361-370 of 508) with videos related to

Sort By:
Pageof 51
AIDS Research and Therapy|January 5, 2023
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistanceRobert A Salata, Beatriz Grinsztejn, Justin Ritz, et al.
The Journal of Infectious Diseases|April 25, 2001
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDSM M Berrey, T Schacker, A C Collier, et al.
Annals of Internal Medicine|July 4, 2001
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV diseaseE L Murphy, A C Collier, L A Kalish, et al.
Optics Express|October 6, 2012
High-energy, ceramic-disk Yb:LuAG laser amplifierM Siebold, M Loeser, F Roeser, et al.
The Lancet. HIV|June 1, 2016
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyAlberto M La Rosa, Linda J Harrison, Babafemi Taiwo, et al.
The New England Journal of Medicine|August 17, 1995
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials GroupP A Volberding, S W Lagakos, J M Grimes, et al.
The New England Journal of Medicine|October 29, 1998
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 TeamD V Havlir, I C Marschner, M S Hirsch, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 20, 2011
Clinical variables identify seronegative HCV co-infection in HIV-infected individualsAjay R Bharti, Scott L Letendre, Tanya Wolfson, et al.
The Journal of Infectious Diseases|July 28, 2011
Identifying the early post-HIV antibody seroconversion periodFrederick M Hecht, Robert Wellman, Michael P Busch, et al.
The Journal of Infectious Diseases|April 5, 2022
Reply to Bottanelli et alJoshua C Cyktor, Ronald J Bosch, Hanna Mar, et al.
Pageof 51